179 related articles for article (PubMed ID: 22890768)
1. Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections.
Boyd NK; Zoellner CL; Swancutt MA; Bhavan KP
Antimicrob Agents Chemother; 2012 Nov; 56(11):6001-2. PubMed ID: 22890768
[TBL] [Abstract][Full Text] [Related]
2. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients.
Bartelink IH; Wolfs T; Jonker M; de Waal M; Egberts TC; Ververs TT; Boelens JJ; Bierings M
Antimicrob Agents Chemother; 2013 Jan; 57(1):235-40. PubMed ID: 23114771
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.
Seyedmousavi S; Mouton JW; Verweij PE; Brüggemann RJ
Expert Rev Anti Infect Ther; 2013 Sep; 11(9):931-41. PubMed ID: 24053274
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of oral voriconazole in patients with cystic fibrosis.
Clifton IJ; Whitaker P; Metcalfe R; Phillip M; Shaw N; Conway SP; Peckham DG
J Antimicrob Chemother; 2011 Oct; 66(10):2438-40. PubMed ID: 21791443
[No Abstract] [Full Text] [Related]
5. Voriconazole concentrations in synovial fluid and bone tissues.
Denes E; Boumediene A; Durox H; Oksman A; Saint-Marcoux F; Darde ML; Gaulier JM
J Antimicrob Chemother; 2007 Apr; 59(4):818-9. PubMed ID: 17329266
[No Abstract] [Full Text] [Related]
6. Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation.
Brüggemann RJ; Antonius T; Heijst Av; Hoogerbrugge PM; Burger DM; Warris A
Ther Drug Monit; 2008 Dec; 30(6):643-6. PubMed ID: 19057370
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring of voriconazole in children.
Chen J; Chan C; Colantonio D; Seto W
Ther Drug Monit; 2012 Feb; 34(1):77-84. PubMed ID: 22210097
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.
Meletiadis J; Al-Saigh R; Velegraki A; Walsh TJ; Roilides E; Zerva L
Antimicrob Agents Chemother; 2012 Jan; 56(1):403-10. PubMed ID: 22064546
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of voriconazole in Japanese quail (Coturnix japonica) experimentally infected with Aspergillus fumigatus.
Tell LA; Clemons KV; Kline Y; Woods L; Kass PH; Martinez M; Stevens DA
Med Mycol; 2010 Mar; 48(2):234-44. PubMed ID: 19548171
[TBL] [Abstract][Full Text] [Related]
10. Pleural diffusion of voriconazole in a patient with Aspergillus fumigatus empyema thoracis.
Stern JB; Girard P; Caliandro R
Antimicrob Agents Chemother; 2004 Mar; 48(3):1065. PubMed ID: 14982812
[No Abstract] [Full Text] [Related]
11. Voriconazole: in the treatment of invasive aspergillosis.
Muijsers RB; Goa KL; Scott LJ
Drugs; 2002; 62(18):2655-64; discussion 2665-6. PubMed ID: 12466006
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints.
Jeans AR; Howard SJ; Al-Nakeeb Z; Goodwin J; Gregson L; Majithiya JB; Lass-Flörl C; Cuenca-Estrella M; Arendrup MC; Warn PA; Hope WW
J Infect Dis; 2012 Aug; 206(3):442-52. PubMed ID: 22634880
[TBL] [Abstract][Full Text] [Related]
13. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis.
Mavridou E; Bruggemann RJ; Melchers WJ; Verweij PE; Mouton JW
Antimicrob Agents Chemother; 2010 Nov; 54(11):4758-64. PubMed ID: 20733046
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis.
Seyedmousavi S; Brüggemann RJ; Melchers WJ; Rijs AJ; Verweij PE; Mouton JW
J Antimicrob Chemother; 2013 Feb; 68(2):385-93. PubMed ID: 23129729
[TBL] [Abstract][Full Text] [Related]
15. Plasma concentrations of voriconazole in falcons.
Schmidt V; Demiraj F; Di Somma A; Bailey T; Ungemach FR; Krautwald-Junghanns ME
Vet Rec; 2007 Aug; 161(8):265-8. PubMed ID: 17720963
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Drug Monitoring of Voriconazole in Children from a Tertiary Care Center in China.
Hu L; Dai TT; Zou L; Li TM; Ding XS; Yin T
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30150475
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis.
George D; Miniter P; Andriole VT
Antimicrob Agents Chemother; 1996 Jan; 40(1):86-91. PubMed ID: 8787885
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis.
Seyedmousavi S; Brüggemann RJ; Melchers WJ; Verweij PE; Mouton JW
Antimicrob Agents Chemother; 2013 Jan; 57(1):303-8. PubMed ID: 23114773
[TBL] [Abstract][Full Text] [Related]
19. In vitro pharmacokinetic/pharmacodynamic modeling of voriconazole activity against Aspergillus species in a new in vitro dynamic model.
Al-Saigh R; Elefanti A; Velegraki A; Zerva L; Meletiadis J
Antimicrob Agents Chemother; 2012 Oct; 56(10):5321-7. PubMed ID: 22869563
[TBL] [Abstract][Full Text] [Related]
20. Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis.
Jeans AR; Howard SJ; Al-Nakeeb Z; Goodwin J; Gregson L; Warn PA; Hope WW
Antimicrob Agents Chemother; 2012 Oct; 56(10):5180-5. PubMed ID: 22825124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
